HYRUM DAVENPORT: Open Payments
NPI 1255567210 · CHUBBUCK, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,149 in 140 payments from 16 companies in 2025. Trend: 2023 $2,020 · 2024 $1,756 · 2025 $2,149
Food & beverage: $2,146Education: $4
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $312 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $311 |
| ABBVIE INC. | 24 | $304 |
| Vanda Pharmaceuticals Inc. | 14 | $258 |
| Neurocrine BioSciences, Inc. | 20 | $227 |
| Alkermes, Inc. | 16 | $208 |
| Teva Pharmaceuticals USA, Inc. | 12 | $148 |
| Tris Pharma Inc | 1 | $117 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
Products named: CAPLYTA, FANAPT, INGREZZA, REXULTI, VRAYLAR, ARISTADA, Onyda XR, ABILIFY ASIMTUFII.
Industry payments across ID — which companies pay providers there.
